FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2528532333> ?p ?o ?g. }

• W2528532333 endingPage "197" @default.
• W2528532333 startingPage "190" @default.
• W2528532333 abstract "Allergic bronchopulmonary aspergillosis (ABPA) affects up to 15% of patients with cystic fibrosis (CF). Corticosteroids are used as first-line therapy, but relapse and adverse effects commonly occur. Case reports have suggested the efficacy of the anti-IgE recombinant humanized monoclonal antibody omalizumab. A retrospective multicenter observational French study retrieved 32 CF patients (11 children and 21 adults) who have received omalizumab for more than 3 months in the context of ABPA. Clinical characteristics, concomitant medications (inhaled and oral corticosteroids, antifungal drugs), lung function, body mass index (BMI), and serum IgE were compared at the start and during the first year of omalizumab therapy. Omalizumab-related adverse effects and costs were also evaluated. No significant difference with omalizumab could be demonstrated with regard to lung function, BMI, or the number of patients receiving oral corticosteroids. At the time of initiation of omalizumab, 56% of patients were receiving oral corticosteroids. Five patients were able to discontinue corticosteroids during follow-up and nine patients were able to reduce their daily dose. A total of 78% of the patients had received antifungal therapy at the time of the initiation of omalizumab. Treatment tolerance was good (12.5% of patients experienced side effects). The median cost of omalizumab treatment was €3,620 per patient per month. Omalizumab may represent a steroid-sparing therapy in CF patients with ABPA. A randomized-controlled trial is urgently required to provide higher level of evidence regarding the efficacy and cost-effectiveness of omalizumab in CF patients with ABPA. Pediatr Pulmonol. 2017;52:190-197. © 2016 Wiley Periodicals, Inc." @default.
• W2528532333 created "2016-10-14" @default.
• W2528532333 creator A5002444114 @default.
• W2528532333 creator A5006649224 @default.
• W2528532333 creator A5011296918 @default.
• W2528532333 creator A5022125342 @default.
• W2528532333 creator A5027594479 @default.
• W2528532333 creator A5034520115 @default.
• W2528532333 creator A5037153621 @default.
• W2528532333 creator A5040342245 @default.
• W2528532333 creator A5082786131 @default.
• W2528532333 creator A5083462576 @default.
• W2528532333 creator A5087522944 @default.
• W2528532333 date "2016-10-07" @default.
• W2528532333 modified "2023-10-17" @default.
• W2528532333 title "Case series of omalizumab for allergic bronchopulmonary aspergillosis in cystic fibrosis patients" @default.
• W2528532333 cites W1493815102 @default.
• W2528532333 cites W1501205955 @default.
• W2528532333 cites W1512622009 @default.
• W2528532333 cites W1985927542 @default.
• W2528532333 cites W1989823290 @default.
• W2528532333 cites W1997855218 @default.
• W2528532333 cites W1998018447 @default.
• W2528532333 cites W2026672451 @default.
• W2528532333 cites W2034866086 @default.
• W2528532333 cites W2067176929 @default.
• W2528532333 cites W2070182900 @default.
• W2528532333 cites W2105239752 @default.
• W2528532333 cites W2115511578 @default.
• W2528532333 cites W2118848330 @default.
• W2528532333 cites W2121500558 @default.
• W2528532333 cites W2125119017 @default.
• W2528532333 cites W2129228230 @default.
• W2528532333 cites W2135649656 @default.
• W2528532333 cites W2157430661 @default.
• W2528532333 cites W2158676024 @default.
• W2528532333 cites W4236893859 @default.
• W2528532333 doi "https://doi.org/10.1002/ppul.23612" @default.
• W2528532333 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27717223" @default.
• W2528532333 hasPublicationYear "2016" @default.
• W2528532333 type Work @default.
• W2528532333 sameAs 2528532333 @default.
• W2528532333 citedByCount "32" @default.
• W2528532333 countsByYear W25285323332017 @default.
• W2528532333 countsByYear W25285323332018 @default.
• W2528532333 countsByYear W25285323332019 @default.
• W2528532333 countsByYear W25285323332020 @default.
• W2528532333 countsByYear W25285323332021 @default.
• W2528532333 countsByYear W25285323332022 @default.
• W2528532333 countsByYear W25285323332023 @default.
• W2528532333 crossrefType "journal-article" @default.
• W2528532333 hasAuthorship W2528532333A5002444114 @default.
• W2528532333 hasAuthorship W2528532333A5006649224 @default.
• W2528532333 hasAuthorship W2528532333A5011296918 @default.
• W2528532333 hasAuthorship W2528532333A5022125342 @default.
• W2528532333 hasAuthorship W2528532333A5027594479 @default.
• W2528532333 hasAuthorship W2528532333A5034520115 @default.
• W2528532333 hasAuthorship W2528532333A5037153621 @default.
• W2528532333 hasAuthorship W2528532333A5040342245 @default.
• W2528532333 hasAuthorship W2528532333A5082786131 @default.
• W2528532333 hasAuthorship W2528532333A5083462576 @default.
• W2528532333 hasAuthorship W2528532333A5087522944 @default.
• W2528532333 hasConcept C126322002 @default.
• W2528532333 hasConcept C141071460 @default.
• W2528532333 hasConcept C141105273 @default.
• W2528532333 hasConcept C151730666 @default.
• W2528532333 hasConcept C159654299 @default.
• W2528532333 hasConcept C197934379 @default.
• W2528532333 hasConcept C203014093 @default.
• W2528532333 hasConcept C2776938444 @default.
• W2528532333 hasConcept C2778564945 @default.
• W2528532333 hasConcept C2778871687 @default.
• W2528532333 hasConcept C2779343474 @default.
• W2528532333 hasConcept C71924100 @default.
• W2528532333 hasConcept C86803240 @default.
• W2528532333 hasConceptScore W2528532333C126322002 @default.
• W2528532333 hasConceptScore W2528532333C141071460 @default.
• W2528532333 hasConceptScore W2528532333C141105273 @default.
• W2528532333 hasConceptScore W2528532333C151730666 @default.
• W2528532333 hasConceptScore W2528532333C159654299 @default.
• W2528532333 hasConceptScore W2528532333C197934379 @default.
• W2528532333 hasConceptScore W2528532333C203014093 @default.
• W2528532333 hasConceptScore W2528532333C2776938444 @default.
• W2528532333 hasConceptScore W2528532333C2778564945 @default.
• W2528532333 hasConceptScore W2528532333C2778871687 @default.
• W2528532333 hasConceptScore W2528532333C2779343474 @default.
• W2528532333 hasConceptScore W2528532333C71924100 @default.
• W2528532333 hasConceptScore W2528532333C86803240 @default.
• W2528532333 hasIssue "2" @default.
• W2528532333 hasLocation W25285323331 @default.
• W2528532333 hasLocation W25285323332 @default.
• W2528532333 hasOpenAccess W2528532333 @default.
• W2528532333 hasPrimaryLocation W25285323331 @default.
• W2528532333 hasRelatedWork W1553814522 @default.
• W2528532333 hasRelatedWork W1732589031 @default.
• W2528532333 hasRelatedWork W1897018659 @default.
• W2528532333 hasRelatedWork W2129582778 @default.
• W2528532333 hasRelatedWork W2260747993 @default.

• next